Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Genor Biopharma Holdings Limited ( (HK:6998) ).
Edding Genor Group Holdings Limited has announced that its board intends to conduct on-market share repurchases from time to time under a general mandate granted by shareholders at the company’s 26 June 2025 annual general meeting. The repurchased shares may be cancelled, held in treasury, sold or transferred as the company deems appropriate, with the board stating that this capital management move is in the interests of the company and its shareholders, though it emphasized that any buybacks will depend on market conditions and regulatory compliance and provided no assurance on timing, volume or pricing, urging investors to exercise caution when dealing in its securities.
The most recent analyst rating on (HK:6998) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Genor Biopharma Holdings Limited stock, see the HK:6998 Stock Forecast page.
More about Genor Biopharma Holdings Limited
Edding Genor Group Holdings Limited, formerly known as Genor Biopharma Holdings Limited, is a Cayman Islands-incorporated company listed in Hong Kong, operating in the biopharmaceutical sector with a focus on developing and commercializing innovative therapies. The group targets healthcare markets where advanced biologic and specialty pharmaceutical products can address unmet medical needs and support long-term growth in the life sciences industry.
Average Trading Volume: 966,926
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.7B
See more insights into 6998 stock on TipRanks’ Stock Analysis page.